Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

  • Quoted phrase not found.
1.

MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome.

Qiu Z, Lin AP, Jiang S, Elkashef SM, Myers J, Srikantan S, Sasi B, Cao JZ, Godley LA, Rakheja D, Lyu Y, Zheng S, Madesh M, Shiio Y, Dahia PLM, Aguiar RCT.

Cell Chem Biol. 2020 Feb 24. pii: S2451-9456(20)30040-4. doi: 10.1016/j.chembiol.2020.02.002. [Epub ahead of print]

PMID:
32101699
2.

Prospective use of the single-mouse experimental design for the evaluation of PLX038A.

Ghilu S, Li Q, Fontaine SD, Santi DV, Kurmasheva RT, Zheng S, Houghton PJ.

Cancer Chemother Pharmacol. 2020 Feb;85(2):251-263. doi: 10.1007/s00280-019-04017-8. Epub 2020 Jan 11.

PMID:
31927611
3.

EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma.

Wu S, Gao F, Zheng S, Zhang C, Martinez-Ledesma E, Ezhilarasan R, Ding J, Li X, Feng N, Multani A, Sulman EP, Verhaak RG, de Groot JF, Heffernan TP, Yung WKA, Koul D.

Clin Cancer Res. 2020 Mar 15;26(6):1395-1407. doi: 10.1158/1078-0432.CCR-19-2549. Epub 2019 Dec 18.

PMID:
31852834
4.

Deep learning of pharmacogenomics resources: moving towards precision oncology.

Chiu YC, Chen HH, Gorthi A, Mostavi M, Zheng S, Huang Y, Chen Y.

Brief Bioinform. 2019 Dec 8. pii: bbz144. doi: 10.1093/bib/bbz144. [Epub ahead of print]

PMID:
31813953
5.

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design.

Rokita JL, Rathi KS, Cardenas MF, Upton KA, Jayaseelan J, Cross KL, Pfeil J, Egolf LE, Way GP, Farrel A, Kendsersky NM, Patel K, Gaonkar KS, Modi A, Berko ER, Lopez G, Vaksman Z, Mayoh C, Nance J, McCoy K, Haber M, Evans K, McCalmont H, Bendak K, Böhm JW, Marshall GM, Tyrrell V, Kalletla K, Braun FK, Qi L, Du Y, Zhang H, Lindsay HB, Zhao S, Shu J, Baxter P, Morton C, Kurmashev D, Zheng S, Chen Y, Bowen J, Bryan AC, Leraas KM, Coppens SE, Doddapaneni H, Momin Z, Zhang W, Sacks GI, Hart LS, Krytska K, Mosse YP, Gatto GJ, Sanchez Y, Greene CS, Diskin SJ, Vaske OM, Haussler D, Gastier-Foster JM, Kolb EA, Gorlick R, Li XN, Reynolds CP, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Raman P, Wheeler DA, Maris JM.

Cell Rep. 2019 Nov 5;29(6):1675-1689.e9. doi: 10.1016/j.celrep.2019.09.071.

6.

Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma.

Li X, Martinez-Ledesma E, Zhang C, Gao F, Zheng S, Ding J, Wu S, Nguyen N, Clifford SC, Wen PY, Ligon KL, Yung WKA, Koul D.

Cancer Res. 2019 Oct 1;79(19):5088-5101. doi: 10.1158/0008-5472.CAN-19-0325. Epub 2019 Aug 15.

PMID:
31416846
7.

A synonymous VHL variant in exon 2 confers susceptibility to familial pheochromocytoma and von Hippel-Lindau disease.

Flores SK, Cheng Z, Jasper AM, Natori K, Okamoto T, Tanabe A, Gotoh K, Shibata H, Sakurai A, Nakai T, Wang X, Zethoven M, Balachander S, Aita Y, Young W, Zheng S, Takekoshi K, Nakamura E, Tothill RW, Aguiar RCT, Dahia PLM.

J Clin Endocrinol Metab. 2019 Apr 4. pii: jc.2019-00235. doi: 10.1210/jc.2019-00235. [Epub ahead of print]

PMID:
30946460
8.

Prospective Clinical Sequencing of Adult Glioma.

Zheng S, Alfaro-Munoz K, Wei W, Wang X, Wang F, Eterovic AK, Shaw KRM, Meric-Bernstam F, Fuller GN, Chen K, Verhaak RG, Mills GB, Yung WKA, Weathers SP, de Groot JF.

Mol Cancer Ther. 2019 May;18(5):991-1000. doi: 10.1158/1535-7163.MCT-18-1122. Epub 2019 Mar 29.

PMID:
30926639
9.

Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma.

Akgül S, Li Y, Zheng S, Kool M, Treisman DM, Li C, Wang Y, Gröbner S, Ikenoue T, Shen Y, Camelo-Piragua S, Tomasek G, Stark S, Guduguntla V, Gusella JF, Guan KL, Pfister SM, Verhaak RGW, Zhu Y.

Cell Rep. 2018 Jul 10;24(2):463-478.e5. doi: 10.1016/j.celrep.2018.06.050.

10.

Profiles of brain metastases: Prioritization of therapeutic targets.

Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB.

Int J Cancer. 2018 Dec 1;143(11):3019-3026. doi: 10.1002/ijc.31624. Epub 2018 Oct 9.

11.

Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma.

deCarvalho AC, Kim H, Poisson LM, Winn ME, Mueller C, Cherba D, Koeman J, Seth S, Protopopov A, Felicella M, Zheng S, Multani A, Jiang Y, Zhang J, Nam DH, Petricoin EF, Chin L, Mikkelsen T, Verhaak RGW.

Nat Genet. 2018 May;50(5):708-717. doi: 10.1038/s41588-018-0105-0. Epub 2018 Apr 23.

12.

TumorFusions: an integrative resource for cancer-associated transcript fusions.

Hu X, Wang Q, Tang M, Barthel F, Amin S, Yoshihara K, Lang FM, Martinez-Ledesma E, Lee SH, Zheng S, Verhaak RGW.

Nucleic Acids Res. 2018 Jan 4;46(D1):D1144-D1149. doi: 10.1093/nar/gkx1018.

13.

Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.

Wu S, Wang S, Gao F, Li L, Zheng S, Yung WKA, Koul D.

Neuro Oncol. 2018 Jan 10;20(1):78-91. doi: 10.1093/neuonc/nox128.

14.

APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death.

Wang Y, Wu S, Zheng S, Wang S, Wali A, Ezhilarasan R, Sulman EP, Koul D, Alfred Yung WK.

Oncotarget. 2017 Apr 21;8(33):54285-54296. doi: 10.18632/oncotarget.17348. eCollection 2017 Aug 15.

15.

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé CG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW.

Cancer Cell. 2017 Jul 10;32(1):42-56.e6. doi: 10.1016/j.ccell.2017.06.003. Erratum in: Cancer Cell. 2018 Jan 8;33(1):152.

16.

Benchmarking: contexts and details matter.

Zheng S.

Genome Biol. 2017 Jul 5;18(1):129. doi: 10.1186/s13059-017-1258-3.

17.

ARID1B alterations identify aggressive tumors in neuroblastoma.

Lee SH, Kim JS, Zheng S, Huse JT, Bae JS, Lee JW, Yoo KH, Koo HH, Kyung S, Park WY, Sung KW.

Oncotarget. 2017 Jul 11;8(28):45943-45950. doi: 10.18632/oncotarget.17500.

18.

Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.

Koul D, Wang S, Wu S, Saito N, Zheng S, Gao F, Kaul I, Setoguchi M, Nakayama K, Koyama K, Shiose Y, Sulman EP, Hirota Y, Yung WKA.

Oncotarget. 2017 Mar 28;8(13):21741-21753. doi: 10.18632/oncotarget.15566.

19.

Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.

Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, Hess KR, Verhaak RGW.

Neuro Oncol. 2017 Jun 1;19(6):786-795. doi: 10.1093/neuonc/now285.

20.

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.

Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ; Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN.

Cell Rep. 2017 Mar 14;18(11):2780-2794. doi: 10.1016/j.celrep.2017.02.033. Erratum in: Cell Rep. 2017 Jun 27;19(13):2878-2880.

Supplemental Content

Loading ...
Support Center